About Us

Background
13 August 2026

Sugar rush: patent strategies in the anti-glycation skincare race

Glycation is a non-enzymatic chemical reaction in which sugars react with proteins, lipids or nucleic acids, leading to the formation of advanced glycation end-products (AGEs). In skin, AGEs accumulate in collagen and can form cross-links between collagen molecules, contributing to reduced skin elasticity and other markers associated with skin ageing.

Glycation has moved from a footnote in dermatological literature to a headline mechanism in cosmetic science. Recent research published by Estée Lauder in the International Journal of Molecular Sciences1 links fructose-induced glycation end-products to fibroblast senescence. The findings add to a growing body of research suggesting that sugar-driven skin ageing extends beyond extracellular protein damage and may involve broader cellular stress mechanisms of relevance to cosmetics innovation.

Importantly, the research suggests that glycation is not merely an extracellular phenomenon affecting collagen and elastin fibres. Rather, elevated sugar exposure appears capable of triggering intracellular glycation events that promote inflammation, impair cell migration, reduce regenerative capacity and accelerate cellular senescence. In patent terms, this broadens the range of potentially protectable innovations beyond conventional anti-glycation ingredients and into screening methods, biomarkers, signalling pathways and regenerative interventions.

For innovators in the cosmetics, dermatology and active ingredient sectors, anti-glycation skincare is becoming an increasingly important area of skin-ageing research. As a result, the associated intellectual property landscape is developing at pace.

A crowded but not saturated claim space

Glycation itself is not new territory in the context of intellectual property. Two patent applications filed over two decades ago disclosed the use of AGEs and their precursors as active ingredients for inducing pigmentation and melanin synthesis in skin (US 2004/076597 A1) and hair (EP 1319392 A2); a reminder that AGEs have long been sought commercially, and that novelty searches in this field need to look well beyond the recent interest in this space.

What has changed is the scientific and commercial context: today’s filings are less likely to claim AGEs as actives in themselves but are more likely to claim compounds or complexes that inhibit AGE formation, disrupt AGE–receptor for advanced glycation end-products (RAGE) binding, restore fibroblast function following glycation-induced stress, stimulate autophagic clearance pathways, reduce senescence-associated secretory phenotypes (SASP) or otherwise modulate the cellular mechanisms now being linked to sugar-induced skin ageing.

This creates both opportunities and challenges for patent applicants. Whilst the underlying biological phenomenon may be well established, a newly identified mechanism of action creates valuable patenting opportunities where a previously unrecognised technical effect has been demonstrated. Drafting strategies therefore need to distinguish carefully between what is already known about glycation chemistry and the novelty of an associated invention.

Real-world examples of anti-glycation patent strategies

The commercial interest surrounding glycation is reflected in a growing range of product launches and patent filings pursuing different technical approaches to the problem.

For example, Provital’s PureBlome platform is positioned around AGE reduction while simultaneously supporting collagen and elastin integrity. This represents a relatively conventional anti-ageing strategy in which glycation inhibition is linked to structural skin benefits.

By contrast, Ichimaru Pharcos has focused on the AGEs–RAGE signalling pathway through its PeoGlow technology. This reflects a more mechanistic approach, targeting a biological pathway associated with inflammation, pigmentation and skin tone regulation.  A recent Japanese patent application from Ichimaru Pharcos (JP 2026031357 A) is directed to compositions capable of inhibiting AGE–RAGE binding, illustrating the increasing focus on specific molecular pathways.

Other applicants have pursued formulation-focused protection. For example, L’Oréal’s international patent application WO 2025/163489 A1 concerns cosmetic compositions containing combinations of vitamin C, dandelion root extract and additional actives intended to inhibit peptide and protein glycation in the skin. This exemplifies a formulation-centred filing strategy aimed at protecting particular combinations of ingredients.

These examples demonstrate that anti-glycation innovation is occurring at multiple levels of the value chain, from active ingredients and botanical extracts through to signalling pathways and cellular stress-response mechanisms. The challenge for applicants is therefore not simply obtaining patent protection, but identifying where genuine technical differentiation lies within a rapidly evolving patent landscape.

A fragmenting, fast-moving landscape

Recent activity shows that it is not a single dominant patent strategy but several parallel approaches. Cosmetics companies, ingredient suppliers and formulators are exploring anti-glycation innovation through fundamental biological research, specific active ingredients, formulation combinations and molecular targets.

Estée Lauder’s work is one example of the growing interest in mechanism-level research. The company has previously filed patents around its longevity platforms, including its SIRTIVITY-LP™ technology (see, for example, US 9750682 B2 and EP 2445511 B1). Other businesses are pursuing different approaches, including AGE reduction, AGE–RAGE inhibition and formulation-based protection.

This distinction between formulation-level and mechanism-level protection is important. A formulation patent directed to a particular botanical extract, peptide or fermentation-derived active may provide useful protection for a specific ingredient platform. A patent family directed to a newly identified biological pathway may potentially support a wider commercial strategy and create barriers for competitors seeking to exploit the same mechanistic insight.

Recent filings suggest a shift from targeting AGE formation itself towards the downstream cellular effects of glycation. The first wave focused largely on identifying compounds capable of reducing AGE formation. The emerging wave is increasingly concerned with understanding and manipulating the downstream consequences of glycation at the cellular level, including inflammatory signalling, senescence pathways, tissue repair mechanisms and cellular resilience.

A broader shift towards cellular mechanisms  

Recent research into glycation reflects a broader trend towards longevity science and so-called “adaptation science”. Rather than treating visible signs of ageing as isolated cosmetic outcomes, researchers are increasingly investigating how environmental stressors alter cellular behaviour over time. AGEs are formed through non-enzymatic reactions between sugars and proteins, lipids or nucleic acids. Accumulation of AGEs has been associated with reduced tissue elasticity, impaired wound healing, inflammation and oxidative stress. Interaction between AGEs and RAGE can activate signalling cascades implicated in chronic inflammation and pigmentation changes, making the pathway particularly attractive from both product development and patent perspectives.

For patent applicants, inventions arising from this research may extend beyond active ingredients themselves. Depending on the technical contribution, protection may be available for screening assays, biomarker panels, methods of identifying responders, ingredient combinations, delivery systems, treatment regimens and manufacturing processes specifically adapted to address glycation-related biological effects.

Practical implications for filing strategy

The clearest lesson from this recent activity is timing. Where clinical or mechanistic data is intended for conference presentation or peer-reviewed publication, priority applications need to be filed ahead of disclosure to preserve novelty across the relevant jurisdictions. This is particularly important in Europe where the European Patent Office (EPO) assesses patentability using an absolute novelty standard so, unlike some jurisdictions, there is no grace period for applicant disclosures.

This risk is particularly acute in scientifically active sectors such as cosmetics and personal care, where companies routinely collaborate with academic institutions, present findings at industry conferences and publish their findings in journals. What may appear to be a marketing announcement can sometimes contain enough technical information to compromise patentability if filing strategy has not been considered in advance.

Companies operating in adjacent formulation spaces should also treat this as a live freedom-to-operate matter: the older patent application filings along with the newer wave of mechanism-specific applications mean that clearance searches in this area need to consider two distinct patent generations of anti-glycation patent activity.

Businesses entering the anti-glycation skincare market should therefore consider a combination of patent landscaping, competitor monitoring and freedom-to-operate analysis. Understanding not only what has been patented, but also where key applicants are directing their future research efforts, can be critical when deciding whether to develop, acquire or license new technologies.

Applicants should also ensure that experimental support is aligned with their intended claim scope. Anti-glycation inventions frequently rely upon biological data demonstrating reductions in AGE formation, modulation of RAGE signalling, restoration of fibroblast activity or improvement in recognised biomarkers of cellular health. The quality and relevance of such data can have a significant impact on patent prosecution and enforcement.

As this technical field becomes more crowded, obtaining patent protection may depend less on identifying entirely new anti-glycation effects and more on demonstrating unexpected technical advantages. Patent applicants should therefore consider how experimental programmes can generate evidence supporting inventive step, whether through improved biological activity, enhanced delivery, synergistic ingredient combinations or previously unrecognised mechanisms of action.

The future of intellectual property in anti-glycation skincare

With glycation increasingly recognised as an important contributor to skin ageing alongside oxidative stress and UV damage, securing robust intellectual property rights has become a growing priority for cosmetics brands.

As the scientific understanding of glycation continues to evolve, we expect to see increasing patent activity directed not only to anti-glycation ingredients, but also to cellular rejuvenation technologies, longevity-inspired skincare platforms, biomarker-driven product development and personalised cosmetic approaches. The companies that succeed are likely to be those that align scientific research, product development and intellectual property strategy from the earliest stages of innovation.

If you would like to know more about how best to use intellectual property to protect your cosmetics innovations, or would like advice on patent filing, freedom-to-operate assessments, patent landscaping or due diligence in the cosmetics and personal care sector, please contact one of our team.

[1] Rella A et al. (2025) Fructose-induced glycation end products promote skin-aging phenotypes and senescence marker expression in human dermal fibroblasts. Int J Mol Sci. 26:616

Services
Sectors
Share